Total
0
Shares
DIAGNOS - President, André Larente - The Market Herald Canada
President, André Larente
Source: La Presse
  • Medical technology company, DIAGNOS (ADK) has revealed a new service agreement with the Colombian Telemedicine Centre (CTMC)
  • The CTMC will use the company’s AI engine CARA to begin screening Colombia’s population for eye-related issues
  • CARA (Computer Assisted Retina Analysis) integrates with existing equipment, and makes standard retinal images sharper, clearer, and easier to read
  • The two parties plan to begin the screening project in two major regions of Colombia in the following weeks
  • Before the market opens, DIAGNOS (ADK) is trading at C$0.17 per share 

Medical technology company, DIAGNOS (ADK) has revealed a new service agreement with the Colombian Telemedicine Centre (CTMC).

The CTMC has chosen DIAGNOS and its artificial intelligence engine, CARA, for a screening project. In alliance with the country's largest specialist centre, the CTMC will use CARA to screen Colombia’s population for eye-related issues.

The CTMC’s founder, Dr Jorge Alberto Velez B, said this will unburden the heavy costs of blindness caused by diabetes.

CARA (Computer Assisted Retina Analysis) is a tele-ophthalmology platform that integrates with pre-existing hardware or software. The tool’s image enhancement algorithms make standard images of a person’s retina sharper, clearer, and easier to read. 

CARA can process results at the point of care, which will empower local technicians. However, specialists will validate the automated results before scheduling follow-ups with patients requiring further treatment.  

The CTMC and DIAGNOS plan to start the screening project in two major regions of Colombia, in the coming weeks.

DIAGNOS’ President, André Larente, commented on the service agreement with Colombia’s Telemedicine Centre. 

“We would like to thank the CTMC for choosing our CARA platform. We believe that CARA is a perfect fit as the main engine of the telemedicine solution.

“After a successful eye screening program with Bayer in 2015, we return to Colombia to engage our AI service into a practical solution for the local community. Along with CTMC, we can add value by making our unique service accessible,” he said. 

Before the market opens, DIAGNOS (ADK) is trading at C$0.17 per share.


Subscribe


More From The Market Herald
Cipher Pharma report $3 million turnaround in 2019

" PharmaTher (CSE:PHRM) signs license agreement for patented Ketamine formulation targeting mental health

PharmaTher (PHRM) has signed an exclusive worldwide license agreement for a patented ketamine formulation.
Nutritional High’s upcoming acquisition enters research agreement

" Theratechnologies (TSX:TH) raises over $58M in public offering

Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds.
TAAT Lifestyles & Wellness (CSE:TAAT) hires new U.S. patent attorney with Fortune 100 experience

" TAAT Lifestyles & Wellness (CSE:TAAT) hires new U.S. patent attorney with Fortune 100 experience

TAAT Lifestyle & Wellness (TAAT) has hired U.S. patent attorney Edmond DeFrank to secure its intellectual property.
MCI Onehealth (TSXV:DRDR) expands digital health footprint

" MCI Onehealth (TSXV:DRDR) expands digital health footprint

MCI Onehealth (DRDR) is accelerating its digital health adoption initiative by acquiring a series healthcare technologies and clinics.